Starving cancer of methionine: what we know, what we don't, and what comes next

Chinese Medical Journals Publishing House Co., Ltd.

Cancer cells are metabolic opportunists. They rewire their biochemistry to grow faster, dodge immune surveillance, and resist treatment. One of the more exploitable vulnerabilities many tumors share is an unusual dependence on a single amino acid: methionine.

Healthy cells can synthesize methionine from its precursor, homocysteine. Many cancer cells cannot. They require an external supply, a dependency sometimes called the Hoffman effect after the researcher who first described it in the 1970s. A new comprehensive review consolidates the evidence for exploiting this weakness therapeutically through methionine restriction (MR), and maps both the promise and the substantial gaps that remain.

What methionine restriction does to tumors

In preclinical studies, restricting methionine intake, either through dietary changes or enzymatic depletion, produces several effects on cancer cells. It hinders proliferation, triggers cell cycle arrest, and enhances the effectiveness of both chemotherapy and radiotherapy. The mechanisms are not limited to simple nutrient deprivation.

Methionine sits at a critical metabolic intersection. It is the precursor for S-adenosylmethionine (SAM), the universal methyl donor that cells use for epigenetic regulation, including DNA methylation and histone modification. Restricting methionine disrupts these processes, altering gene expression patterns that tumors rely on for survival and growth. MR also shifts the cellular redox balance and affects autophagy, the process by which cells recycle their own components under stress.

In animal models, these laboratory effects translate into measurable tumor suppression and extended survival, though the magnitude varies significantly across cancer types.

Early clinical signals

The review identifies early-phase clinical trials that have begun testing methionine restriction in combination with established therapies. Preliminary results suggest the approach is safe and tolerable. Some trials are investigating biomarkers that might predict which patients are most likely to respond, a critical step for any metabolic therapy where tumor biology varies widely between individuals.

The clinical evidence remains thin, however. Most trials have been small, and none have yet demonstrated definitive efficacy in a randomized, controlled setting. The review is transparent about this limitation: large-scale clinical trials are essential before methionine restriction can be considered a validated treatment strategy.

Practical obstacles and open questions

Restricting methionine in humans is not straightforward. Dietary methionine restriction requires patients to adhere to a highly specific and restrictive eating pattern, which is difficult to sustain. Methionine is found in most protein-rich foods, including meat, fish, eggs, and dairy. An alternative approach, enzymatic depletion using methioninase to break down methionine in the blood, avoids the compliance problem but introduces its own pharmacological challenges.

The review highlights MR-mimetic drugs and targeted supplements as potential solutions for improving patient compliance, but these remain in development. Long-term effects of methionine restriction on healthy tissues are also poorly understood. Methionine is essential for normal cellular function, and chronic restriction could carry risks that short-term studies have not captured.

Where the field is heading

The most intriguing frontier involves combining methionine restriction with immunotherapies and targeted treatments, including CAR-T cell therapy. The logic is that MR could sensitize tumors to immune attack by altering their epigenetic landscape and metabolic defenses. Whether this logic holds in patients is unknown.

The review calls for large-scale clinical trials evaluating MR across diverse cancer types, with attention to sustainability, safety, and the identification of optimal patient populations. If the approach works, it would offer a treatment strategy that exploits a metabolic vulnerability rather than relying solely on cytotoxic drugs, potentially with fewer side effects for patients whose tumors are methionine-dependent.

That is a significant "if." The preclinical data are encouraging, the biological rationale is sound, and the early clinical signals are positive. But the history of cancer research is filled with metabolic strategies that worked in mice and failed in humans. Methionine restriction has not yet cleared that bar.